Introduction
Until the second half of 1990's, patients with deep vein thrombosis (DVT) needed to be admitted to a hospital and treated with intravenous unfractionated heparin for at least 5 days along with coumarins; this regimen requires close laboratory monitoring to be both effective and safe. Two landmark trials 1,2 showed that patients could be safely treated at home with low-molecular weight heparins, drugs that have proven effective when administered in fixed, weight-adjusted doses, one or two times a day without laboratory monitoring. Shortly afterwards, home treatment of DVT became a standard practice worldwide.
We recently revised more than 273,000 hospital discharge records across the last 8 years (2005-2012) in our Department, and we found that only a very small proportion of cases (0.083%) were discharged with an ICD-IX-CM code that led to an attribution to the Diagnosis Related Group 128 (Cei M, unpublished data; Figure 1 ). Even if this exceptionally low value could be underestimated due to attribution of cases to other codes, we regard this as quite surprising. In fact, in clinical trials, many patients were excluded from home treatment, and outside the research context, physicians should have been even more cautious. We were therefore prompted to critically review the reasons that have led to patients being excluded from home treatment in clinical trials and the reasons that still suggest hospital admission for DVT patients. We focused on DVT of the lower limbs only in this review.
Discussion
The problem of exclusion from home treatment In randomised clinical trials (RCT), a large proportion of eligible patients are excluded from home treatment: 1491/2230 (66.9%) in a study by Levine 1 and 216/692 (31.2%) in a trial by Koopman 2 . The proportion of excluded patients along with partial in-hospital initial treatment of those patients regarded as treated 'at home' were already identified as fundamental problems in a Cochrane review from Othieno 3 . This represents a clear lack of generalizability, the proportion of patients excluded from home treatment was not so high in , and current practices seem to be even more aggressive 15 . This could be due to, at least in part, the fact that study patients were excluded because of a wide range of conditions, some of which are peculiar to experimental context and are not usually considered in clinical practice ( Table 1) . On the other hand, a carefully designed pathway for outpatient treatment seems to be less permissive; up to 70% of patients were excluded from home treatment in a series from Shapiro 16 . Indeed, other exclusion reasons may include both conditions related to the clinical status of patients and those related to social, geographic and logistic constraints (Table 2) . However, cancer (even when metastatic) should not be considered in itself a reason for exclusion from treatment at home 17 . Moreover, Hyers reported that home treatment was more common in suburban and rural areas than in urban settings in a large, multicentric study 18 .
Burden of venous thromboembolism
Approximately one third of DVT patients have some degree of pulmonary involvement 19 , and trials have therefore included patients with pulmonary embolism (PE) that was not 'severe' or symptomatic. Moreover, the treatment of PE at home has been formally assessed 20 . Nowadays, we have been provided with a validated tool (the Hestia Criteria, Table 3 ) that safely identifies patients who do not need to be admitted for the management of PE 21 . Patients with extensive iliofemoral DVT or phlegmasia cerulea dolens, which are conditions that carry a high risk of severe post-thrombotic syndrome or those that require parenteral or opioid analgesia, were usually excluded from RCT, although they should been included. It may be reasonable to consider alternative strategies for these patients, including putting them on unfractionated heparin until they have been evaluated for surgical thrombectomy or catheter-directed thrombolysis 22, 23 . Bilateral lower limb DVT should raise the suspect of inferior vena cava thrombosis and, in turn, possibly caval atresia 24 , especially in the young; these patients should be therefore admitted for extensive evaluation and treatment.
unrevealing DVT progression or assessing non-overt bleeding. In future, newer anticoagulants not needing laboratory monitoring would further increase the proportion of patients who will not seek medical advice during the period of active treatment.
Conclusion
Outpatient treatment of DVT is generally safe and effective, even when associated with low-risk PE. However, some patients should be admitted because of thromboembolic extension, high risk of bleeding or relevant comorbidities. It is advisable to implement clinical pathways to support the decision to safely assign a patient to outpatient management. Table 2 do not deserve specific comments, apart from the presence of comorbidities, which are the most frequently reported cause of hospital admission. As in the case of bleeding, this decision was left at the physician's discretion. Taken together, these two matters of exclusion lessen the strength of evidence in favour of the safety of home treatment, because the risk of an exclusion bias is not negligible.
Unresolved issues and concerns
It is unknown to what extent the real world follow-up consuetudes differ from the research context. In RCT, patients are more likely to be regularly followed by visiting nurses 27 , have facilities to communicate with physicians responsible for the treatment and have the availability of fasttrack hospital evaluation in case of symptoms. Clinical pathways should be assured to minimise the risk of outpatient treatment 28 . Standard practices may not be as effective in The fear of bleeding Many patients in RCT are admitted because of active bleeding or the perceived high risk of bleeding. A miscellanea of clinical conditions have been considered to fulfil this criterion of exclusion, including the presence of bleeding diathesis (defined as thrombocytopenia < 100,000 × 10 6 /L or INR > 1.4), uncontrolled or malignant hypertension, renal or hepatic failure (Figure 2) , recent surgery (especially neurologic or ophthalmic) or lumbar puncture, recent gastrointestinal (within 1 month) or intracerebral bleeding (within 6 months) or the concomitant use of antiplatelet agents. To our knowledge, any formal score has never been adopted to exclude such patients from home treatment, and the decision to admit the patient usually relies largely on clinical judgement alone. Indeed, serious bleeding seems to be related more to the patient's characteristics than to the treatment setting 25 , and bleeding risk tools have not been shown to be very accurate, at least in the elderly DVT patients Competing interests: none declared. Conflict of interests: none declared.
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